Genmab — August 2019
-
Ja, du har ret Bulder - tricket er først og fremmest IKKE at nedjustere (over for den nye investorbase i US).. og så kan man pludselig godt vride tallene lidt. Men det forekommer noget i modstrid med Davids synspunkter udtrykt tidligere ved mange lejligheder.
-
Enig Bulder.
-
Det overrasker mig relativ meget de tager valuta effekten nu og bruger det til en opjustering. Så kan man i hvert fald ikke kalde dem konservative mere i deres forecast
-
Men som ventet så giver valuta korrigering ikke ret meget. De har jo også massiv store udgifter i dollars som også bliver opskrevet
-
Stigning på 170 ansatte. Og det tempo tror jeg ikke falder meget de næste 12-24 mdr
-
Revenue
We expect our 2019 revenue to be approximately DKK 4,800 million, an increase of DKK 200 million compared to the previous guidance. Our projected revenue for 2019 primarily consists of DARZALEX royalties of DKK 2,885 million, an increase of DKK 200 million from the previous guidance due to positive impact of USD/DKK exchange rates movements. The DARZALEX royalties are based on estimated net sales of USD 3.0 billion in 2019. We continue to project DARZALEX milestones of approximately DKK -
KKJ se side 18 der har du de data
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind